Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER_GOV × vactosertib × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Capecitabine 27 Cisplatin 23 tislelizumab 22 Oxaliplatin 22 Gemcitabine 22 apatinib 21 Paclitaxel 18 Irinotecan 17 Carboplatin 17 Docetaxel 15 Bevacizumab 15 Fluorouracil 12 Drug Therapy 12 pembrolizumab 10 camrelizumab 10 Cyclophosphamide 10 Radiation 9 Vinorelbine 8 S 1 (combination) 8 Cetuximab 8 Rituximab 7 Erlotinib Hydrochloride 7 Leucovorin 6 Gefitinib 6 Albumin-Bound Paclitaxel 6 toripalimab 5 sintilimab 5 pyrotinib 5 fludarabine 5 Trastuzumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04893252 2022-11-30

Vactosertib and Durvalumab in Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡